目的:总结同种异体肾移植手术的手术配合。方法:回顾总结30例肾移植的手术过程及手术配合。结果:30例患者术程顺利,术中无并发症发生。结论:充分的术前准备、术中密切配合是肾移植手术顺利进行的关键,及时准确应用各类药物、严格无菌管理,对保证手术成功及肾移植受者长期存活具有重要意义。
摘要:目的: 报道同卵双生子间肾移植效果,探讨免疫抑制剂及激素的使用、鉴定同卵双生子的方法以及术后随访。 方法 :个案报道结合文献综述。 结果 :手术获得成功。术后随访8月,患者恢复良好。 结论 :同卵双生间的肾移植安全有效,术后不需要使用免疫抑制剂也能维持移植肾功能正常。Abstract: Objective: Reported the effects of renal transplantation between identical twins,explored the use of immunosuppressive drugs and glucocorticoid, identification method of the identical twins and postoperative followup . Methods :Combining case report and literature review. Results :The operation is success.Followup in 8 months,the patient recover well. Conclusion : The renal transplantation between identical twins is safe and effective,the immunosuppressant is not need for the postoperative patients to maintain the graft`s function.
ObjectiveTo examine the characteristics of Rhodococcus equi (R. equi) infection for better awareness of this disease.MethodsThe clinical data of a patient with pulmonary abscess caused by R. equi after renal transplantation were reported. We also reviewed the reports of infections caused by R. equi.ResultsThe clinical manifestations and laboratory examination of the patient were consistent with the characteristics of R. equi infection. The growth of R. equi was found in sputum and blood culture. The follow-up data showed that the treatment was effective. Literature search identified 23 similar patients. In all the 24 patients (containing this one), the time of infection after renal transplantation ranged from 4 months to 11 years. There were 21 patients with cumulative pulmonary infection, and 10 patients had a clear epidemiological history of direct or indirect contact with horses. Eighteen patients improved after regular antibacterial treatment or surgical treatment.ConclusionsOpportunistic infections caused by R. equi mainly affect transplant recipients and other patients with lower immunity. Infections caused by R. equi may affect many organ systems with various manifestations. The optimal therapy is not established due to the rarity of this infection. Clinicians should select antibiotic agents rationally based on antimicrobial susceptibility testing and treatment response of patients.
目的 探讨肾移植患者非结核分枝杆菌（NTM）病临床特点及分子诊断。 方法 回顾性分析2011年4月1例皮肤软组织NTM感染的肾移植患者的临床特点，并以其病变组织DNA为模板，聚合酶链反应（PCR）扩增hsp65基因和rpoB基因序列，测序比对鉴定其NTM菌种。结合文献复习NTM病及分析分子生物学技术在移植患者NTM感染诊断中的作用。 结果 该肾移植患者系皮肤软组织胞内分枝杆菌感染，临床特点与结核病极其相似，难以进行鉴别诊断。PCR扩增、测序的结果显示hsp65产物和rpoB产物序列与胞内分枝杆菌GeneBank中FJ643456.1及CP003324.1序列100%一致。 结论 NTM病的临床表现与结核病相似，分子生物学方法鉴定菌种对移植患者胞内分枝杆菌病的诊断有帮助。
The experience on management of abnormal blood vessels in 128 cases of donor kidney during the tailoring operation was reported. The various techniques used for different types of abnormal arteries and veins, and the critical points which should be paid attention to have been discussed. It was concluded that the multiple renal arteries should be treated in a single renal artery and anastomosed with internal iliac artery or/and external iliac artery. The appropriate management given to abnormal renal blood vessels during the tailoring operation may shorten the warm ishemia time, ensure the renal blood supply, reduce the renal vasular complication, and promote the recovery of renal function.
目的报告1例分期肝肾联合移植，并探讨分期肝肾联合移植治疗技术及其效果。方法对1例晚期乙型肝炎肝硬变伴肾功能衰竭患者实施原位肝移植术，所用免疫抑制方案为环孢霉素A与甲基强的松龙联合用药，于肝移植术后3个月行肾移植术。结果肝移植术后肝功能恢复良好，但肾功能持续恶化，经血液透析治疗无效而行肾移植术。患者肝肾联合移植术后9个月，一般情况良好，移植肝和移植肾功能均正常。结论对肝移植后各种原因导致的肾功能衰竭，当血液透析治疗无效时可再行肾移植术。同时，免疫抑制剂用量并未增加。
胰腺移植主要包括单独胰腺移植（pancreas transplantation alone, PTA）、肾移植后胰腺移植（pancreas after kidney transplantation, PAK）和胰肾联合移植（simultaneous pancreaskidney transplantation, SPK）。与其它实体大器官移植一样，胰腺移植成功的真正转折始于20世纪70年代末。随着新型免疫抑制剂的开发和应用、器官保存技术的改进和外科技术的日臻成熟，胰腺移植在全球范围内得到迅猛开展，胰腺移植受体及器官存活率显著提高。据国际胰腺移植登记中心（International Pancreas Transplant Registry, IPTR）记录，至2001年10月，全球已实施17 000余例胰腺移植，其中美国有11 500余例，胰腺移植后患者1年生存率超过95%，3年生存率接近90%； 移植胰腺1年和3年有功能生存率分别为83%和77%［1，2］。自1966年首例SPK在美国Minnesota大学成功实施以来，SPK已成为治疗Ⅰ型糖尿病合并肾功能衰竭的常规方法，全世界迄今为止已实施的胰腺移植中约90%采用该术式［3，4］。
Kidney transplantation is an ideal treatment for patients with end-stage renal disease. Circulating alloantibodies against donor human leukocyte antigens and blood group antigens can impair allografts, shorten allograft survival, and limit access to kidney transplantation. Furthermore, the presence of donor specific antibodies is associated with increased incidence of antibody-mediated rejection and decreased graft survival following transplantation. Plasmapheresis, an extracorporeal therapy directed at removing plasma proteins that has been found to minimize the effects of perioperative sensitization in kidney transplantation. Plasmapheresis enables transplantation across the barrier of ABO blood group incompatibility. In addition, it is also an important approach for the treatment of antibody-mediated rejection. Therefore, studying the application of plasmapheresis in perioperative period of kidney transplantation is expected to increase the chance of transplantation and improve the outcomes following transplantation. This article introduces the application of plasmapheresis in the perioperative period of kidney transplantation.